Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Orchestra BioMed granted 133,000 inducement stock options to seven new employees, vesting over four years under its 2025 New Hire Inducement Plan.

Rhea-AI Summary

Orchestra BioMed (OBIO) granted stock options for an aggregate 133,000 common shares to seven newly hired employees on September 1, 2026. The options were issued under the company’s 2025 New Hire Inducement Plan as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Each grant will vest over a four-year period. Orchestra BioMed states that it is disclosing these awards to comply with Nasdaq’s inducement grant disclosure requirements.

News Explained

The September 1 grants give seven new employees options covering 133,000 common shares, creating potential future dilution for existing holders rather than reporting that those shares have already been issued; vesting occurs over four years.

Market Context

-1.28% was OBIO’s 24-hour reaction to the June 2 inducement-grant announcement. That prior compariso...

Analysis

-1.28% was OBIO’s 24-hour reaction to the June 2 inducement-grant announcement. That prior comparison adds context to today’s grant disclosure; net selling remains a risk factor, and the active S-3 is a resale registration without company proceeds.

Key Figures

Shares under options: 133,000 shares Recipients: 7 employees Grant date: September 1, 2026 +2 more

5 metrics

Shares under options 133,000 shares Aggregate grant to seven newly hired employees

Recipients 7 employees New hires receiving stock options

Grant date September 1, 2026 Date of stock-option grant

Vesting period Four years Vesting schedule for each employee's options

Nasdaq listing rule 5635(c)(4) Rule cited for the inducement awards

Historical Context

5 past events · Latest: Aug 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 27	Conference participation	Neutral	-3.0%	CEO presentation and investor meetings scheduled for September 16
Aug 20	Conference participation	Neutral	-2.2%	CEO presentation and investor meetings scheduled for September 9 and 10
Aug 10	Q2 earnings report	Neutral	-1.8%	Q2 results included cash update and pivotal-program progress
Jun 29	Index inclusion	Positive	+12.0%	Added to Russell 3000 and Russell 2000 indexes
Jun 02	Inducement grants	Neutral	-1.3%	Options granted to five newly hired employees under inducement plan

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions were negative after four of five events; the sole positive reaction followed Russell index inclusion.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on September 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 133,000 shares of the Company’s common stock to seven newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options granted to each new employee will vest over a four-year period.

Orchestra Biomed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Orchestra BioMed

Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue^® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com

Media Contact:
Nina Premutico
Orchestra BioMed
npremutico@orchestrabiomed.com

FAQ

What did Orchestra BioMed (OBIO) announce regarding stock options for new employees?

Orchestra BioMed announced that its Compensation Committee granted stock options to purchase an aggregate of 133,000 shares of common stock to seven newly hired employees on September 1, 2026, as inducement awards under the 2025 New Hire Inducement Plan.

Under which plan were the OBIO inducement stock options granted?

The stock options were granted under the Orchestra BioMed Holdings, Inc. 2025 New Hire Inducement Plan. The company describes these options as inducement awards that were material to each new employee’s decision to enter employment with Orchestra BioMed.

How do the Orchestra BioMed (OBIO) inducement stock options vest for new employees?

The company states that the stock options granted to each of the seven new employees will vest over a four-year period. No additional vesting milestones or conditions beyond the four-year schedule are detailed in the announcement.

Why is Orchestra BioMed (OBIO) disclosing these inducement grants?

Orchestra BioMed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4), which governs equity awards granted as a material inducement to new employees and requires public disclosure of such grants.